What we do Gennex Laboratories Ltd is an Indian pharma company manufacturing bulk drugs, intermediates, and biotech products with a strong export focus and vertically integrated operations. |
Founded in 1,985 |
Market share Leading vertically integrated pharma company with robust product portfolio in expectorants, muscle relaxants, analgesics, and antifungals. |
Problem solved Provides essential active pharmaceutical ingredients and biotech products meeting global quality standards to support healthcare needs worldwide. |
Top clients or who we serve Serves pharmaceutical companies and global markets including Germany, UK, Spain, Singapore, Canada, Iran, Bangladesh, Pakistan; mostly B2B exports. |
Key management - |
Our journey and innovations Incorporated in 1985, became public in 2007; implemented GMP and CGMP; diversified into biotech in 2007-08; acquired Deccan Remedies in 2023. |
Where we operate Primarily India with exports to Germany, Egypt, Iran, Peru, Spain, Vietnam, Guatemala, and others. |
Top products or what we offer Active pharmaceutical ingredients including expectorants, muscle relaxants, analgesics, antifungals, and biotech products. |
Top brands - |
Raw materials needed Chemical intermediates and pharmaceutical-grade raw materials for active drug manufacturing. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue largely recurring from pharmaceutical ingredient manufacturing and biotech products with global customer base. |
Our industry position Recognized player in Indian pharma API manufacturing with appreciable export footprint and compliance certifications. |
Financial highlights FY 2024-25 revenue ₹137.9 crores, net profit ₹18.12 crores, 59% rise in consolidated profit, steady EBITDA growth. |
Geographical revenue split Major revenue from India (₹32.61 crore) and significant exports to Egypt, Iran, Peru, Vietnam, and others. |
Order book - |
Whats driving growth Capacity expansion, increased R&D, securing new APIs, and expanding export markets drive growth. |
Our future plans Plans to add APIs, enhance production capacities, and explore funding options to accelerate growth. |
Our green promise - |
Our people and values Focus on professional management and talent retention; committed to ethical business practices. |
Key challenges ahead Raw material availability, regulatory compliance, and intensified global competition. |
Interesting facts Acquired majority stake in Deccan Remedies in 2023; ISO and GMP certifications validate quality. |
Risks and strategy Mitigating supply chain risks and regulatory challenges through continuous compliance and diversification. |
